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Summary 
  
Although oxycodone is widely used as perioperative analgesic, it’s respiratory profile 
(particularly the extent of respiratory depression with respect to morphine) remains to be 
fully characterised. With ethics approval, ASA I-II adults for elective surgery under 
general anaesthesia were randomised to receive placebo (n=6), morphine 0.1 mg.kg
-1
, or 
oxycodone 0.05 mg.kg
-1
, 0.1 mg.kg
-1
, 0.2 mg.kg
-1
  (n=12 in each active group). The study 
drug was injected intravenously after ten minutes steady state of spontaneous breathing. 
Monitoring was continued for thirty minutes and data obtained from previously validated 
wet wedge spirometer breathing system.  Any patients meeting the predefined respiratory 
depression criteria in the first ten minutes of study drug administration received 
incremental intravenous naloxone.  Mean minute volume decreased from baseline in all 
study groups. All study groups showed significant respiratory depression compared to 
placebo (P=0.000018, P<0.000001, P<0.000001 and P=0.000016 for oxycodone 0.05, 
0.1, 0.2 and morphine 0.1 respectively).  The mean percentage reduction from baseline 
was 88.6%, 74.4%,, 53.3%, and 22.6% for oxycodone 0.05, 0.1, 0.2 and morphine 0.1 
groups respectively, with significant dose dependent differences between oxycodone 
groups (P=0.0007). The extent and speed of onset of oxycodone induced respiratory 
depression was dose dependent and greater than an equivalent dose of morphine. 
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Introduction 
Oxycodone is a semi-synthetic thebaine derivative (14-hydroxy-7, 8-dihydrocodine) that 
has been used in clinical practice since 1917. Clinically it demonstrates analgesia and 
anti-nociception effect that are predominantly attributed to its µ-opioid receptor agonist 
actions. Although animal work suggests that there could a possible agonist action at κ 
opioid receptors especially the κ2 subunit ligand that may contributing to some of its 
actions, clinically this is yet to be confirmed and it is unclear whether the κ2 subunit 
ligand really exists or rather the changes can be attributed to heterodimerization of the 
opioid receptors [1-3].  
Oxycodone is widely used as an analgesic both in acute and chronic pain practice. 
Besides an increased oral bioavailability it also confers an added advantage of a more 
rapid onset of analgesia in comparison to morphine [4-7]. Though often considered 
equianalgesic to morphine, the equivalence dose for parenteral conversion between the 
two opioids is quite variable (a range of 0.64 to 1.0 quoted in published literature) [8-9]. 
Oxycodone is clinically as effective or more so than morphine, with fewer side-effects . It 
is used orally, having good bioavailability as well as intravenously via a patient 
controlled analgesia (PCA) regime [6,10,11]. It is thought to be more effective in the 
treatment of visceral pain, possibly due to activity on the κ receptor, as well as a more 
favourable profile in the context of any immunosuppressive effects [12-19].  
There are further isolated reports suggesting that besides a faster onset of intrinsic 
antinociceptive effect, oxycodone administration also demonstrates a more rapid onset of 
its respiratory effects as compared to morphine, however the evidence is lacking in terms 
of randomised controlled trials [20-23]. The intention of this placebo controlled 
randomised pilot study, was to demonstrate and characterise the respiratory effects of 
different doses of intravenous oxycodone and compare them to morphine. This study 
employs a respiratory model of spontaneously breathing patients under general 
anaesthesia (previously validated in similar studies characterising effects of opioids on 
respiratory function), and was conducted in the anaesthetic induction room prior to 
surgery [20-24]. We performed this study with a primary objective of measuring the 
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effect and extent of different doses of intravenous oxycodone on minute ventilation and 
comparing this to morphine and placebo in identical conditions. As a secondary objective 
this study also performed preliminary observations of the effect of naloxone 
administration to such changes in the minute ventilation. 
 
Method 
Patients 
After obtaining local research ethics committee approval, this double blind, randomised, 
placebo controlled, parallel group pilot study was performed in adults (aged 18-55 years), 
scheduled for elective surgery of more than 30 minutes duration under general 
anaesthesia. 54 ASA grade 1-2 patients, weighing 45-100 kg and /or body mass index 
BMI < 30 gave informed consent and were randomised to one of the five groups in Table 
1. Patients with previous history of anaesthetic complications, substance abuse or 
allergies to morphine, oxycodone or naloxone, long-term opioid use, known conditions 
predisposing to respiratory depression, gastro-esophageal reflux disease were all 
excluded. 
 
The study medication was prepared by a third party, to maintain the blinding of the 
investigators. In the anaesthetic room, the clinical investigator sited routine clinical 
monitoring and intravenous access. Anaesthesia was induced with propofol 3-5 mg.kg
-1
   
and maintained with 1 MAC isoflurane, throughout the monitoring period, in a 40% 
oxygen/air mixture via a laryngeal mask airway ensuring no discernible leak. The 
sampling line was attached to the end of the laryngeal mask. Once breathing 
spontaneously, patients were connected to the modified wet wedge spirometer breathing 
system (Figure 1) based on the principles described by O’Connor et al [24]. The wet-
wedge spirometer is a low resistance device that allows continuous volume employing a 
reservoir bag and relief valve without the need for introduction of any additional valves. 
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Figure 1. Wet-wedge spirometer. 
 
Using the ‘bag-in-bottle’ principle, tidal volume is transmitted to the wet wedge 
spirometer (Figure 2), which is constructed from Perspex, and takes the form of a sector 
of a hollow cylinder, floating in a tank of water, counterbalanced by a weighted bar.  The 
useable volume of the wedge is approximately 900 ml.  Angular displacements of the 
wedge are transmitted via a gear system to the spindle of a DC/DC angular position 
transducer (Model No. DS3810, Denny & Giles Potentiometers Ltd., Christchurch, UK). 
The movement of the spirometer wedge thus causes a resulting change in output voltage 
which is proportional to changes in the volume. This signal is digitised and stored in a 
notebook PC running a virtual instrument (VI) program implemented in LabVIEW 
(National Instruments Corp). The VI displayed a continuous waveform indicating the 
displacement of the spirometer wedge throughout the study period.  Fresh gas flow into 
the system was exactly balanced by suction, controlled by two needle valves in series, 
one for coarse adjustment and the other for fine adjustment.   
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Figure 2.  Block diagram of the breathing system. 
 
The spirometer was calibrated before each patient study, with air using a 250 ml syringe 
connected to the input port of the spirometer.  The suction was adjusted until the 
spirometer wedge remained stationary when there was no tidal flow in or out of the 
breathing system.  The patient was then connected to the spirometry breathing system 
once satisfactory spontaneous breathing was established. 
Recordings of respiratory rate, end-expiratory carbon dioxide, oxygen saturation and 
minute volume were recorded. After a 10 minute period of baseline respiratory steady 
state, the study was given intravenously by the blinded investigator. If at any point during 
the first 10 minutes after the study medication was administered, the respiratory rate had 
fallen by >33% and/or the end-expiratory CO2 had risen by >1.5 kPa, then naloxone 
400mcg was administered intravenously. If at any stage, the following were to occur: 
apnoea > 1 minute, end-expiratory CO2 >10 kPa or SpO2 < 90%; the patient’s lungs were 
then manually ventilated for one minute, aiming for SpO2 > 96% and end-expiratory 
CO2 < 8, followed by a trial of spontaneous respiration, with the same criteria as above 
for restarting manual ventilation. Spirometry readings were continued for a period of 30 
minutes after the study drug was given. At the end of the 30 minute period, spirometry 
was discontinued and a standard breathing system re-attached to the patient. The patient 
was then transferred to the operating theatre and anaesthesia was then continued as per 
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routine practice for the surgery. The clinical anaesthetist was informed of the identity of 
the study drug by the third party who had prepared the drug initially, so as to ensure that 
the patient received the appropriate analgesic management intra- and post-operatively. 
Re-emergence and recovery was conducted as normal, with all patients discharged safely 
to the ward when standard recovery criteria had been met. 
 
Study Drug Dose Number 
Oxycodone (mg.kg
-1
) 0.05 12 
Oxycodone (mg.kg
-1
) 0.1 12 
Oxycodone (mg.kg
-1
) 0.2 12 
Morphine (mg.kg
-1
)
 
0.1 12 
Placebo (ml) 5  6 
 
Table 1. Study drug groups 
 
Statistical analysis 
The sample size of 54 patients (12 per active drug, 6 in the placebo group) was chosen to 
detect differences of >20% in minute volume after opioid administration (alpha = 0.05, 
beta = 0.2). Mean (±SD) minute volume percentage change in each group from the 
baseline was calculated. Minute volume percentage changes for each active group were 
compared from baseline to post administration of opioid and pre-naloxone administration 
time point to the end of study using 2-tailed, paired t-test. Comparison to placebo was 
done using 2-tailed, unpaired t-test. A value of P < 0.05 was considered significant. To 
calculate the difference in extent and rate of onset of respiratory depression between all 
the groups, an ANOVA test was used. Probability values of P<0.05 were considered 
significant. 
Results 
Out of 54 patients recruited the data of two patients could not be extracted due to 
technical failure and was excluded from final analysis. Both of these patients were in the 
oxycodone 0.2 mg.kg
-1
 group.  Patient characteristics are shown in Table 2. 
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Drug Placebo Morphine 
Oxycodone 
(0.05mg.kg
-1
 ) 
Oxycodone 
(0.1mg.kg
-1
 ) 
Oxycodone 
(0.2mg.kg
-1
) 
No. of Patients 6 12 12 12 10 
Age (Years) 37.3(26-54) 36.8(18-51) 37.2 (20-51) 32.33 (23-49) 33.2 (20-46) 
Weight (Kg) 74.8 (54-92) 68.8 (56-80) 70.4 (56-104) 74.6 (53-95) 72.5 (57-95) 
M:F 4:2 7:5 7:5 7:5 3:7 
 
Table 2.  Patient characteristics. Data are mean (range) or absolute numbers 
 
 Placebo 
n=6 
Oxycodone 
0.05 mg.kg
-
1 
 
Oxycodone 
0.1 mg.kg
-1
 
 
Oxycodone 
0.2 mg.kg
-1
 
 
Morphine 
0.1 mg.kg
-1
 
n 6 12 12 10 12 
zero doses 
of naloxone 
6 3 0 0 9 
one dose of 
naloxone 
0 9 8 4 3 
More than 
one dose of 
naloxone 
0 0 4 6 0 
Mean time 
to first dose 
(s) 
N/A 100 92 67 275 
P values      
 
Table 3. Table showing the number of patients in each group who received naloxone. 
 
In the placebo group, there was no significant change in minute volume (P=0.714) from 
baseline and hence no naloxone was given to the patients in that group. An average time 
at which naloxone was administered within each of the active groups was calculated as an 
indicator of the onset of respiratory depression, as set out in the study criteria, and 
calculated the mean minute volume in each of the groups at that time point. There was a 
significant reduction in minute volume from baseline (SD) in the morphine group 22.6 
(10.4) (P=0.000003).  In the three oxycodone groups, mean minute volume decreased 
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significantly from baseline (P=0.000067, P<0.000001, P<0.000001) for oxycodone 0.05, 
0.1, 0.2 respectively) and there was a significant difference in the fall in minute volume 
between the three oxycodone groups (ANOVA P=0.0007). For all patients, the % 
decrease from baseline (SD) was 53.3 (27.2), 74.4 (12.9) and 88.6 (13.5) for the 
oxycodone 0.05, 0.1 and 0.2 mg.kg
-1
 respectively.  All study groups showed significant 
respiratory depression compared to placebo (P=0.000018, P<0.000001, P<0.000001 and 
P=0.000016 for oxycodone 0.05, 0.1, 0.2 and morphine 0.1 respectively).  Table 3 shows 
the number of patients in each group who received naloxone, the number of doses given, 
and the mean time of the first naloxone administration.  Figure 3 shows the mean percent 
changes in volume for patients who recieved naloxone.  It can be seen that following 
naloxone administration, all naloxone groups showed a significant improvement in 
minute volume from the pre-naloxone values (P= 0.000011, P<0.000001, P<0.000001 for 
oxycodone 0.05, 0.1, 0.2 respectively). 
 
 
 
 
Figure 3. Graph showing mean (SD) percent change in minute volume at various times 
for all patients who received naloxone.  The maximal reduction in minute volume 
following administration of the study drug (‘Depressed’) is shown, followed by the 
change in minute volume three minutes after administration of naloxone (‘Recovered’).  
The minute volume changes 10 and 15 minutes after administration of the study drug 
(‘SD+10’ and ‘SD+15’) are also shown 
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Discussion 
Oxycodone a synthetic opioid has action on both µ and κ opioid receptors [8,12,16]. It 
has a high oral bioavailability (60-90%) and an analgesic potency 30-50 % greater than 
morphine [9]. The increased potency may contribute to a stronger anti-nociceptive effect 
at equivalent dose of morphine hence the ongoing debate about the actual equivalence 
rate after parenteral administration. Oxycodone may produce a dose dependent decrease 
in respiration although the exact nature and comparison to morphine remains to be 
substantiated using randomised controlled trials [8,9,16,25]. The primary objective of this 
pilot study was to characterise the respiratory profile of oxycodone in a spontaneously 
breathing anaesthetised patient and compare it with morphine when administered 
intravenously. The additive effect of opioids and volatile maintained general anaesthesia 
on spontaneous ventilation facilitates a sensitive model that has been used in previous 
studies evaluating the respiratory effects of opioids [24, 26].  
Using this model of patients under general anaesthesia on spontaneous ventilation, the 
wet-wedge spirometer in our pilot study characterised the respiratory depression 
produced by various doses of oxycodone. The mechanical signal from the spirometer was 
digitised and stored in a notebook PC running a virtual instrument (VI) program 
implemented in LabVIEW (National Instruments Corp).  
The equivalent dose when converting between parenteral morphine and oxycodone is 
variable with a suggested ratio of 0.65 to 1.0 when converting between the two. 
Interestingly some reports have quoted an even higher conversion ratio of 1.5 when 
converting the two drugs. Three doses of oxycodone were chosen (0.05, 0.1 and 0.2 
mg.kg
-1
) in our study reflecting doses that are a 0.5, 1.0 and 1.5 conversion ratio 
respectively. The different doses of oxycodone were chosen on the assumption that the 
middle dose maybe equi-analgesic to morphine, and the other two were half and double 
respectively. 
All three doses of oxycodone used in the study provided a dose dependent statistically 
significant respiratory depression. The rate of onset of this respiratory depression was 
significantly quicker as well compared to morphine. The mean minute volume decreased 
significantly from baseline and there was a significant difference in the fall in minute 
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volume between the three oxycodone groups. This would correlate well with the dose 
dependent direct effect on the respiration.  
In the morphine group, three out of the twelve patients needed a single dose of naloxone 
each. This was in contrast to the patients in the low dose oxycodone (0.05 mg.kg
-1
) group, 
in which nine out of 12 patients received a single dose of naloxone. In the oxycodone 0.1 
mg.kg
-1
group, all 12 patients received at least one dose with four patients receiving a 
second dose and in the 0.2 mg.kg
-1
 group, all ten patients received naloxone with three of 
the ten receiving a second dose, two receiving a third dose, and a further one patient 
receiving four doses in total. The increased naloxone requirement in the oxycodone 
groups suggest that the extent of respiratory depression characterised by decrease in the 
minute volume was greater even in the oxycodone 0.05 mg.kg
-1
 group as compared to 
patients receiving morphine.  
There was a significant difference in the onset of respiratory depression (measured by the 
time needed to receive first naloxone dose) between the four groups. In patients who 
reached the respiratory threshold values, the mean time to first naloxone dose was 275 
seconds in the morphine group, and 100, 92, and 67 seconds in the oxycodone 0.05, 0.1, 
0.2 mg.kg
-1
 groups respectively. 
Oxycodone has similar lipid solubility to morphine and similar protein binding with clear 
agonist properties at the µ opioid receptor. It is thought, however, that its active 
metabolite- oxymorphone- has a great µ receptor binding ability compared to morphine, 
and could be the reason for the faster onset, respiratory depression and potency of the 
drug [10, 27-30].  
Absence of placebo control for naloxone precludes any definite statement about the 
reversal following naloxone administration, though it might be conjectured that naloxone 
administration did stop the ongoing negative trend in change of minute volume. In our 
model, this comparison of oxycodone and morphine has shown that the extent and speed 
of onset of oxycodone induced respiratory depression was significantly greater than that 
seen in the morphine group. It was seen that naloxone increased minute volume in all 
four opioid groups with some higher dose oxycodone patients requiring multiple doses to 
maintain respiratory depression criteria above threshold values. 
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These preliminary results suggest that respiratory depression may be greater with 
oxycodone than an equivalent analgesic dose of morphine and a further larger study is 
needed.  
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